

ESPI Current Report

Number: 3/2025
Date of preparation of January 28, 2025
Company Genomtec SA based in Wrocław

Title	Filing of a second patent application for an oncology project
--------------	--

Legal basis: Article 17 section 1 of MAR - confidential information

Report Content: The Management Board of Genomtec SA with its registered office in Wrocław ("Issuer", "Company") informs that today, i.e. on 28 January 2025, it received information about filing an application on behalf of the Company to the British Patent Office for a patent for an invention in the area of diagnostics of single-nucleotide genetic changes. The Company's patent strategy assumes extending the protection of the invention in question in the international PCT procedure. Filing an application for patent protection of the developed technology is the culmination of complex laboratory work, which resulted in the creation of a methodology allowing the use of modified SNAAT/LAMP technology in highly precise diagnostics of single-nucleotide genetic changes, including in the area of oncology. The developed technique is particularly important in the case of mixtures containing both mutated and non-mutated material, which is the case, for example, in the case of samples in the so-called liquid biopsy technique. At the same time, the potential applications of the method go beyond oncology and medicine – the method can also be used wherever diagnostics of genetic variants are necessary, both in clinical diagnostics and, among others, in veterinary medicine and food safety. The developed methodology, combined with the technique described in report 27/2023, allows for comprehensive diagnostics of clinically significant genetic changes that constitute the basis for making, for example, a decision on the choice of therapy, among others, in oncology.

According to the Issuer, patent protection in the oncology project may have a positive impact on the M&A process conducted by the Company.

Signatures of persons representing the Company:

Michał Wachowski - Member of the Management Board

